Navigation Links
SPO Medical to Conduct Live Investor Meeting on April 29, 2008

Using WallStreet VIPs' New Platform to Reach Wide Investor Audience

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today that it will be delivering a live, virtual investor presentation, using WallStreet VIPs' new platform on April 29, 2008 at 1 PM Eastern Daylight Time (EDT).

NEW YORK, April 10 /PRNewswire-FirstCall/ -- "SPO Medical is a company on the move, though many investors still are not familiar with us," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "We just reported our 2007 full year results with record sales; we added two new professional products, the finger PulseOx 6000(TM) and the hand-held PulseOx 6100(TM), and increased our network of distributors to 38 countries. Using WallStreet VIPs, we disseminate our story to the investor community broadcasting directly on the internet. It's a very effective way to reach out to the broader investor community, since presenters and investors can meet easily and conveniently from their respective offices."

"WallStreet VIPs is a 21st century productivity solution to the challenges of scheduling quality time for live meetings and provide great value added for every public company's comprehensive Investor Relations strategy in today's global village and permanent time constraints," stated Jerry Cahn, Ph.D., J.D., President of WallStreet VIPs. "Investor meetings are the life-blood of public companies. They enable the companies to maintain contact with the investor community educating and updating them on the company's business strategy and developments. CEOs traditionally engage in road shows traveling from city-to-city to meet investors impacting their time and attention that should be devoted to running their businesses."

For a free invitation to SPO Medical's virtual meeting, please register at

About SPO Medical

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

About Wall Street VIPs

WallStreet VIPs is the 21st century productivity solution to the challenges of scheduling quality time, live meetings with potential and existing investors. When integrated with face-to-face meetings for the most serious investors making commitments, VIPs become a key part of every company's comprehensive investor relations strategy. WallStreet VIPs coordinates the whole program, scheduling the event, inviting qualified investors, coaching the presenter on using the platform, helping make the investor presentation compelling and providing details on the attending audience. For details, see:

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor Contacts

SPO Medical: Target 3 Communications:

Michael Braunold, President & CEO Eugene Feyman, Director

+1-805-823-8163 +1-646-827-0009

SOURCE SPO Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
Breaking Biology News(10 mins):